


CLAIMS

1. A compound of formula



(I)

wherein m represents 1, 2 or 3;

each R^1 independently represents a hydrogen or halogen atom;

one of R^2 and R^3 represents halogen, nitro, amino, hydroxyl, or a group selected from (i) C_1 - C_6 alkyl optionally substituted by at least one halogen atom,

(ii) C_3 - C_8 cycloalkyl, (iii) C_1 - C_6 alkoxy optionally substituted by at least one halogen

atom, and (iv) C_3 - C_8 cycloalkyloxy, and the other of R^2 and R^3 represents a hydrogen or halogen atom;

n represents 0, 1 or 2; and

R^4 and R^5 each independently represent a hydrogen atom or a C_1 - C_6 alkyl group optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;


or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1, wherein m is 1.

3. A compound according to claim 1 or claim 2, wherein R^3 represents a hydrogen atom.

4. A compound according to any one of claims 1 to 3, wherein n is 1.

5. A compound according to claim 4, which has the following stereochemistry:



- 5
6. A compound according to any one of claims 1 to 5, wherein R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally substituted by at least one hydroxyl group.
- 10 7. A compound according to claim 1, wherein
- m represents 1;
- each R¹ represents a hydrogen atom;
- one of R² and R³ represents a halogen atom, and the other of R² and R³ represents a hydrogen atom;
- 15 n is 0, 1 or 2; and
- R⁴ and R⁵ each independently represent a hydrogen atom or a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂ and -(CH₂)₃OH.
8. A compound according to claim 1, wherein
- 20 m represents 1;
- each R¹ represents a hydrogen atom;
- one of R² and R³ represents a halogen atom, and the other of R² and R³ represents a hydrogen atom;

n is 0, 1 or 2; and

one of R⁴ and R⁵ represents a hydrogen atom or -CH₃ and the other of R⁴ and R⁵ represents a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂ and -(CH₂)₃OH.

5 9. A compound being selected from any one of:

2-Chloro-5-[(3S)-3-hydroxy-4-(methylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(3S)-3-hydroxy-4-(ethylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

10 2-Chloro-5-[(3S)-3-hydroxy-4-(1-methylethylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(3R)-3-hydroxy-4-(methylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

15 2-Chloro-5-[(2R)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

20 2-Chloro-5-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

25 2-Chloro-5-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-3-(dimethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-3-(dimethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(1S)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide hydrochloride,

2-Chloro-5-[(1S)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

5 2-Chloro-5-[(1R)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide hydrochloride,

2-Chloro-5-[(1R)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

10 2-Chloro-5-[(1R)-2-(ethylamino)-1-hydroxyethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(1R)-1-hydroxy-2-[(3-hydroxypropyl)amino]ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(2S)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

15 2-Chloro-5-[(2S)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

20 2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,


2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide benzoic acid salt,

2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

25 and all pharmaceutically acceptable salts and solvates thereof.

10. A process for the preparation of a compound according to claim 1, which comprises:


(i) when *n* is 0, reacting a compound of formula



(II)

wherein m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III), HNR^4R^5 , wherein R^4 and R^5 are as defined in formula (I); or

- 5 (ii) when n is 1, reacting a compound of formula




(IV)

wherein m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or


- 10 (iii) when n is 2, reacting a compound of formula

50



wherein L^1 is a leaving group and m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or

- (iv) when n is 1, reacting a compound of formula



wherein L^2 is a leaving group and m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above;

- and optionally after (i), (ii) (iii) or (iv) carrying out one or more of the following:

- converting the compound obtained to a further compound of formula (I)
- forming a pharmaceutically acceptable salt or solvate of the compound.

11. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. A process for the preparation of a pharmaceutical composition as claimed in claim 11 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in any one of claims 1 to 9 with a pharmaceutically acceptable adjuvant, diluent or carrier.

13. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 for use in therapy.

14. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of rheumatoid arthritis.

15. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of an obstructive airways disease.

16. Use according to claim 15, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease.

17. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of osteoarthritis.

18. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of atherosclerosis.

19. A method of treating rheumatoid arthritis or osteoarthritis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I)

or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9.

20. A method of treating an obstructive airways disease which comprises administering
s to a patient a therapeutically effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9.